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Abstract
Point-of-care devices technology are a promising way towards the recognition of path-
ogens in early-stage diagnosis, which is critical for the success of inexpensive treatments
as opposed to the high costs of managing the disease. The integration of immunoassays
with read out circuitry allows the implementation of diagnostic devices for their use by
untrained personnel, without compromising reliability. In the following chapter, three
different biosensors based on lab-on-a-chip (LoC) and microfluidic technologies were
designed, assembled and tested for pathogen diagnosis. The devices allowed the effec-
tive detection of the human papilloma virus, Mycobacterium tuberculosis and Chagas
parasite in shorter times and with smaller sample volumes than those required by
current clinical diagnosis techniques. All devices were benchmarked against commercial
techniques in terms of cost and time requirement per test.
Keywords: microfluidics, biosensors, electroimmunosensors
1. Introduction
Diagnostic of pathogenic driven diseases has become a global concern due to the rapid growth
of infectious diseases around the world [1]. For decades, pathogen detection has been mainly
attained through cell culture, nucleic amplification and enzyme-linked immunoassays, which
rely on tedious protocols and are generally time consuming [2]. According to the World Health
Organization (WHO), novel technologies for pathogen diagnosis urgently need to address
issues regarding affordability, sensitivity, specificity, ease of use, robustness, response time
and deliverability to end-users [3]. For this reason, lab-on-a-chip (LoC) and microfluidic
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systems, with the inclusion of biosensors, emerge as an attractive alternative due to their low
sample volume requirements, rapid response, and ease of integration [4].
The first generation of electrochemical biosensors emerged from the incorporation of immobilized
enzymes on conventional electrodes. They were firstly thought for laboratory instruments, but
rapidly penetrated into the medical device industry thanks to diagnostic companies [5]. Enzyme-
based biosensors exploit the specificity of enzymes towards a particular substrate for sensing
purposes [4]. In such devices, immobilized enzymes serve as mediators, easing electron transport
from the active site to the electrode [6] andproviding a clear signal for substrate recognition. Due to
the rather limited availability of substrates, enzyme-based biosensors were rapidly replaced in the
medical industry with immunoassays. Antibody-based biosensors rely on the transduction of
signals from immobilized antibodies upon binding of specific analytes. This type of biosensors is
well accepted in themedical industry for the detection of proteins specific to a particular disease or
condition. Electroimmunosensors are antibody-based biosensors that employ electrochemical
transducers to obtain an electrical response [7]. The charge transport capacity of the electrodes
employed in electroimmunosensors can bemonitored via cyclic voltammetry (CV) or as an electri-
cal impedance change via electrochemical impedance spectroscopy (EIS). These two techniques, in
conjunctionwithmicrofluidics, allow the fabrication ofwhat is usually known as LoCdevices.
In the following chapter, we present the design and fabrication of three different systems for
detection of human papilloma virus (HPV), tuberculosis and Chagas. Detection of HPVand tuber-
culosis is effectively achieved by electroimmunosensor LoC technology, while Chagas relies on a
microfluidic device for separation and impedance measurement for sensing. The devices are
benchmarked against commercial diagnostic devices in terms of ease of use, time of testing and cost.
2. Case of study: HPV
The human papilloma virus (HPV) is a double DNA chain viral pathogen that is sexually transmit-
ted. HPV has been associated with several diseases, such as cervical lesions, condylomas and
cervical cancer [8]. Recent studies estimate that between 50 and 80% of sexually active women
around theworld have been infectedwithHPVat least once in their lifetime [9]. There aremore than
100 different types of HPV strands, some of which are low risk and are generally associated with
genital warts. Some other strands, such as HPV 16, are more virulent andmay lead to the develop-
ment of cervical cancer [10]. It is estimated that every year some 500,000 new cases of HPV are
diagnosedwith condyloma or cervical cancer, which cause around 240,000 deaths in theU.S. [11].
Currently, the preferred assays for diagnosis of HPV infections are hybrid capture (HC) and
polymerase chain reaction (PCR) [12]. HC is based on the hybridization of denatured cells with
a RNA probe followed by capturing the hybrids via specific binding to antibodies. Signal is
amplified by chemiluminescent compound binding through a specific enzyme. This is attained
by the conjugation of a secondary antibody with an enzyme that catalyzes the chemilumines-
cent reaction. Conversely, in PCR, virus detection is performed by the amplification of target
DNA aided by DNA polymerases.
Regardless of the accuracy and standardization of laboratory testing, reducing long times
of diagnosis and the requirement of specialized personnel, remain as major challenges.
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Miniaturization in LoC devices has been widely explored to attain these issues. For instance,
Kim et al. [13] developed a microcantilever-based biosensor for the electrical detection of HPV
by its conjugation with specific proteins and magnetic beads. Similarly, Huang et al. [14]
implemented electrical impedance spectroscopy (EIS) and differential pulse voltammetry on
graphene/gold electrodes to detect specific DNA strands of HPV. Although these biosensors
have proved to enhance the sensitivity of the detection, Their manufacturing processes are not
cost-effective, limiting their accessibility.
Hereby, an antibody-based biosensor with an electronic readout is presented and compared
with HC2 and RT-PCR cobas® 4800. The system consists of almost 100 individual test cham-
bers, and was tested with real samples for the detection of HPV.
2.1. Methodology and results
2.1.1. Fabrication of the biomicrosystem
The biomicrosystemwas fabricated by self-assembly technique as described in [15]. Briefly, a gold
nanolayer was deposited on a poly(methyl methacrylate) (PMMA) substrate via physical evapo-
ration. A second PMMA slide was patterned by laser engraving with 2 mm wells organized in 7
rows and 14 columns. The slide was adhered to the gold-coated PMMAwithmethylene chloride.
Wells were equipped with square holes for electrical connectors. A total of 98 independent bio-
sensors were embedded as shown in Figure 1.
Antibody immobilization was attained by placing 4 μL of 97% 4-aminothiolphenol (ATP)
(Sigma-Aldrich, USA) in each well. Excess thiols were removed by further ethanol and deionized
water rinses. 4 μL of monoclonal antibody (mAb) 5051 was added to each well for immobiliza-
tion via covalent coupling to the pendant amine group. The biomicrosystem was incubated for
1 h at 37C and washed with PBS and deionized water.
2.1.2. HPV detection
HPV detection was achieved by EIS and cyclic voltammetry (CV) measurements, and was
compared with PCR technique. Samples were obtained from a specialized clinical laboratory
Figure 1. Biomicrosystem for HPV detection.
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(PATOLAB, Colombia) from women between 25 and 40 years old. Changes on the impedance
were recorded for biomicrosystems with only the gold layer (gold); the gold layer and the thiol
(gold-4-ATP); and the gold layer, the thiol and the mAb 5051 (gold-4-ATP-mAb 5051). 10 μL of
sample with or without HPV 16 was pipetted in each well and incubated for 1 h at 37C. Wells
were washed with deionized water prior to impedance measurements.
2.1.3. Results
Samples placed in gold-4-ATP-mAb 5051 wells and containing HPV 16 exhibited an imped-
ance change of approximately 40% when compared with initial measurements, while samples
without HPV 16 showed an impedance change of less than 5%. Changes in impedance
between clean wells and wells of 40 samples with HPV 16 are shown in Figure 2.
Impedance changes were significant in wells were the mAb 5051 was immobilized due to its
affinity towards HPV 16 proteins.
2.2. Cost analysis
An analytic hierarchy process (AHP) was performed to compare our biomicrosystem with RT-
PCR cobas® 4800 and HC2 Test in terms of cost, effectiveness, time required and test analysis.
RT-PCR cobas® 4800 allows an automated sample preparation without the need of thawing or
mixing, giving results in less than 20 min for up to 94 different samples. HC2 test utilizes in vitro
nucleic acid hybridization assay with signal amplification towards 13 different HPV specimens.
Cost was considered as the local price of performing one test; effectiveness as the probability of
encountering false positives or false negatives; time required as the total time per test; and test
analysis as a compounded weigh of the probability of sample contamination, the capacity of
Figure 2. Changes in impedance after exposure to HPV 16 samples.
Biosensing Technologies for the Detection of Pathogens - A Prospective Way for Rapid Analysis114
the test to diagnose with blood in the sample and the number of different HPV genotypes that
can be detected per test.
Information for RT-PCR cobra® 4800 and HC2 Test was obtained from three independent
specialized laboratories; namely SIPLAS, Quimiolab and Fundacion Santafe de Bogota. Matrix
pairwise comparisons based on the scale of Saaty were then conducted on the software Expert
Choice 11.5 (ExpertChoice, USA) to evaluate each method [16]. Table 1 shows the criteria
selected and the values for each of the tests.
Global relative weighs of the biomicrosystem, RT-PCR cobas® 4800 and HC2 Test were of
0.343, 0.458 and 0.199, respectively. Our biomicrosystem lags behind the PCR technique due
to its inability to detect more than one genotype of HPV. Nonetheless, since the biomicrosystem
consists of 98 independent wells, an increase on genotype detection can be achieved by
varying the types of antibodies immobilized per well.
3. Case of study: tuberculosis
Tuberculosis (TB) is a disease caused by the pathogenic bacterium Mycobacterium tuberculosis.
This disease can be effectively controlled by early diagnosis and treatment [17]. Conventional
detection technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent
assay (ELISA), and immunochromatographic assay. PCR utilizes oligonucleotides towards a
specific gene in M. tuberculosis [18]; ELISA is used as a solid phase immunoassay for the
detection of an antigen [19]; and immunochromatographic assay is based on the analysis of
antigens in a sandwich-based format [20]. These detection technologies exhibit; however, issues
regarding long-time of analysis and lack of reliability and sensitivity, which ultimately limit their
ability to recognize M. tuberculosis [21]. Furthermore, other techniques require various reagents
and fluorescent or chemiluminescent labeling for sensing, exhibit low-yields, and may even
require further purification steps [22]. Currently, TB is the leading cause of death in people
within the most economically productive age-groups and the second deadliest infectious disease
in the world [23]. Since diagnosis represents a vital link in the TB control chain, new cost-
effective detection platforms are required to achieve quality results in a shorter time span [24].
An alternative route is the use of biosensors, which have attracted significant attention due to
their high sensitivity, short analysis time, ease of miniaturization and cost-effectiveness.
Test Cost Time
per test
Contamination
probability
Effectiveness with
blood in sample
Amount of HPV
genotypes per test
Effectivity
of the test
Biomicrosystem Less than
commercial tests
2 h High High 1 High
RT-PCR cobas
4800
55 USD 2–3 h None, process
is automatized
Medium 14 High
Hybrid Capture 2 63 USD 2–3 h Low High 13 High
Table 1. Information used for matrix pairwise comparison.
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Biosensors can be manufactured by the immobilization of biomolecules via self-assembled
monolayers (SAMs), which can be generated with the use of thiols, disulfides, silanes, or acids
[25]. Among biosensors, immunosensors are devices based on antigen–antibody interaction for
the recognition of specific proteins. This interaction is usually transduced into an electrical
readable signal [4, 5, 7]. Impedance analysis, a technique based on the measurement of changes
in electrical properties of a conductive material [26], is used in this type of biosensors, provid-
ing label-free detection and avoiding chemical amplification schemes [27].
In this section, we show the design, manufacturing and testing of biomicrosystems based on
printed circuit board (PCB) platforms, with 40 independent electro-immunosensors for the
detection of the 6 kDa early secretory antigen target-6 (ESAT-6), which is an immunodominant
secreted protein involved in the virulence ofM. tuberculosis [28]. Sensors were integrated into a
microfluidic system that allows the use of a minimum volume of sample per test. Human
serum albumin (HSA) was employed as a negative control. Each electro-immunosensor was
comprised of a gold nanolayer with an immobilized polyclonal antibody (pAb) attached by a
thiol-based SAM. Without the need of intrusive or destructive methods, it was possible to
detect probe-target interactions and verify all manufacturing stages of the biomicrosystem via
impedance analysis at different frequency ranges [29].
3.1. Materials and methods
3.1.1. PCB design and manufacture
Each biomicrosystem was mounted on a double-layer FR-4 PCB of 142  48.7 mm with 2 oz.
thickness of copper. Electrodes were patterned on the top layer while interconnection tracks
were placed on the bottom layer with CadSoft Eagle Professional 7.4.0. The PCB bottom
surface was laminated with antisolder and the top layer was left uncovered for further material
deposition. The PCB electrical conductivity was verified through PeakTech 3725 multifunction
digital tester (PeakTech, Ahrensburg, Germany).
3.1.2. Lift off and gold deposition
A uniform gold nanolayer was physically evaporated to form the electrodes at the top layer of
the board. Briefly, the substrate top surface was laminated with a dry photosensitive film
(LAMINAR® E9200) in the RLM 419P (Bungard Elektronik, Windeck, Germany) laminator.
The substrate was exposed to UV light to promote free-radical polymerization. The laminated
substrate was subjected to a developing process and a uniform gold nanolayer was physically
evaporated on the laminated substrate through physical vapor deposition (PVD) with thermal
evaporator Edwards Auto 306 (Moorfield Nanotechnology Limited, Cheshire, UK). A 3 A
current, vacuum pressure of 4 105 mbar and an evaporation rate of 0.12 nm/s were used
over a tungsten slide for 100 mg gold evaporation. Finally, photoresist sacrificial layer was
removed with stripper (Bungard Elektronik, Windeck, Germany), obtaining an 80 nm gold
nanolayer on 35 μm copper surfaces. The electrical conductivity of individual electrodes on the
board of each biomicrosystem was verified using a PeakTech 3725 multifunction digital tester
(PeakTech, Ahrensburg, Germany).
Biosensing Technologies for the Detection of Pathogens - A Prospective Way for Rapid Analysis116
3.1.3. Biomicrosystem development
A 121  20.8 mm PMMA slide with 2 mm wells organized in two rows and 20 columns was
adhered to the top of the PCB top layer using TESA® 4965 double-sided tape and subsequently
fixed with screws (Figure 3a), miming a well plate with individual wells for each electrode.
Reagents were deposited inside each well for the biosensor fabrication (Figure 3b) and electri-
cal connectors were placed between each well for electrical measurements (Figure 3c). Three
biomicrosystems were fabricated and tested in different batches, each biomicrosystem
containing 40 independent electro-immunosensors, which were individually measured for
each batch (Figure 3d) to assure the reproducibility and repeatability of the manufacturing
process. A total of 120 electro-immunosensors were tested.
3.1.4. Reagents immobilization
SAM were produced in each well following the procedure in [15]. Shortly, 10 μL of 20 mM
4-aminothiophenol (4-ATP) solution were added as cross-linkers in each well and left at room
temperature for 4 h. To remove excess of thiols, wells were washed with ethanol and deionized
water. 10 μL of 100 μg/mL pAb 45073 solution were added into each well. The system was
stored at 4C overnight. PBS and deionized water were used to remove excess biomolecules.
3.1.5. Immobilization tests
Impedance measurements of each well of the electro-immunosensor were according to the
diagram shown in Figure 3d and using an impedance analyzer (Agilent 4294A) at a frequency
Figure 3. (a) Schematic representation of the biomicrosystem, (b) illustration of the self-assembly process for each well, (c)
actual image of the fabricated biomicrosystem, and (d) equivalent measurement circuit of the biomicrosystem.
Detection of Pathogens Using Microfluidics and Biosensors
http://dx.doi.org/10.5772/intechopen.72443
117
range from 40 to 120 Hz, 120 to 200 Hz and 200 to 280 Hz. Frequencies were selected as
reported in [15]. Sensors were manufactured in three main stages, first a gold nanolayer (Au),
followed by a gold nanolayer with a SAM of 4-ATP (Au + ATP), and finally a gold nanolayer
with a SAM of 4-ATP and pAb 45073 (Au + ATP + pA). Eight replicates of the impedance
measurements were collected at each stage for the specific frequencies above. Impedance
analysis was also performed for analyte recognition in the presence of both 0.5 μg/mL of
ESAT6 (Au + ATP + pA-ESAT6) (positive control) and HSA (Au + ATP + pA-HSA) (negative
control). After analyte deposition, wells remained at room temperature and under static
conditions for 1 h prior to electrical measurements.
3.2. Results
3.2.1. Immobilization testing by impedance analysis
The average impedance magnitude of the three manufacturing stages of the sensors (Au,
Au + ATP, Au + ATP + pA) was determined by its response to an AC current as a function of
frequency [30]. To determine the variation of the copper with gold evaporated prior to the
immobilization (conductive layer), 40 individual wells of three biomicrosystems were mea-
sured by impedance analysis at different frequency ranges. The mean value of the 120 wells
was 0.1588Ωwith a standard deviation of 0.0142, 0.1591Ωwith a standard deviation of 0.0142,
and 0.1584 Ω with a standard deviation of 0.0102 Ω, for ranges 40–120 Hz, 120–200 Hz and
200–280 Hz, respectively. This suggested small variance and good reproducibility of the
manufacturing processes of all wells regardless of the fabrication batch. The largest significant
differences within immobilization stages were observed for 40 and 120 Hz (Figure 4, Table 2).
Figure 4. Analysis of impedance variation for the three mainmanufacturing stages. (a) Impedance magnitude at 40–120 Hz,
(b) impedance magnitude at 120–200 Hz, and (c) impedance magnitude at 200–280 Hz.
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In this range, there is a non-significant variation of impedance (3.81%) between the first two
manufacturing stages, Au and Au + ATP. Nonetheless, a 31.21% of impedance variation
between Au and Au + ATP + pA was measured. Also, impedance measurements between the
first two manufacturing stages varied 5.51% and 2.16%, from 120 to 200 Hz and from 200 to
280 Hz, respectively. Similarly, variations of 11.4 and 14.37% between Au and Au + ATP + pA
were detected at frequencies ranges of 120 to 200 Hz and 200 to 280 Hz, respectively. Finally,
there was a correspondence between the impedance value of the last immobilization step and
negative controls, which was 0.20 Ω [29].
Frequencies |Z| Au |Z| 4-ATP |Z| Ab
Average
(μ) Au
Standard
Deviation (σ) Au
Average (μ)
4-ATP
Standard Deviation
(σ) 4-ATP
Average
(μ) Ab
Standard
Deviation (σ) Ab
40 0.1526 0.0167 0.1466 0.0145 0.1986 0.0070
50 0.1523 0.0165 0.1482 0.0142 0.1997 0.0067
60 0.1517 0.0169 0.1472 0.0141 0.2004 0.0065
70 0.1523 0.0167 0.1475 0.0144 0.1996 0.0065
80 0.1530 0.0160 0.1473 0.0139 0.2009 0.0068
90 0.1528 0.0159 0.1470 0.0144 0.2018 0.0071
100 0.1530 0.0165 0.1471 0.0142 0.2016 0.0068
110 0.1525 0.0159 0.1470 0.0143 0.2003 0.0070
120 0.1532 0.0166 0.1472 0.0140 0.2009 0.0070
130 0.1629 0.0159 0.1542 0.0220 0.1819 0.0083
140 0.1627 0.0156 0.1540 0.0213 0.1821 0.0084
150 0.1629 0.0158 0.1540 0.0216 0.1814 0.0083
160 0.1624 0.0157 0.1549 0.0219 0.1815 0.0084
170 0.1624 0.0159 0.1534 0.0216 0.1807 0.0081
180 0.1627 0.0155 0.1535 0.0216 0.1812 0.0085
190 0.1624 0.0154 0.1535 0.0218 0.1809 0.0082
200 0.1629 0.0155 0.1537 0.0216 0.1805 0.0084
210 0.1612 0.0088 0.1653 0.0052 0.1846 0.0022
220 0.1614 0.0089 0.1646 0.0052 0.1844 0.0020
230 0.1605 0.0088 0.1655 0.0051 0.1850 0.0021
240 0.1605 0.0089 0.1644 0.0051 0.1839 0.0019
250 0.1619 0.0087 0.1649 0.0051 0.1846 0.0021
260 0.1613 0.0089 0.1646 0.0052 0.1838 0.0023
270 0.1611 0.0090 0.1646 0.0049 0.1845 0.0019
280 0.1610 0.0087 0.1654 0.0047 0.1843 0.0022
Table 2. Impedance magnitude values (mean and standard deviation) of the manufacturing stages at 40–280 Hz.
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3.2.2. Detection of protein ESAT6
Impedance analysis was used to verify the detection of ESAT6 as means of M. tuberculosis
diagnosis. 0.5 μg/mL ESAT-6 were used as a positive control and 0.5 μg/mL HSA as a negative
control, and their detection was compared to the dot blot assay. Figure 5 and Table 3 show that
the frequency range from 40 Hz to 120 Hz has the largest significant variation in impedance
among all investigated ranges. Figure 5c and d shows significant changes in other frequency
ranges (120–200 Hz and 200–280 Hz). Between 40 and 120 Hz, the detection of the M. tubercu-
losis protein has an impedance increase of 171% compared to the impedance measured for the
negative control (HSA), which showed a negligible impedance variation. No overlapping
values between the negative and the positive control were identified. All the results of the
negative controls were under 0.20 Ω while impedance values for the positive controls were
above 0.54 Ω. This defined an interval where protein detection is not attainable.
3.3. Analytic hierarchy process (AHP) for comparison of the biomicrosystem with
traditional detection techniques
AHP was utilized to study the viability of the electro-immunosensor compared with tradi-
tional TB diagnostic techniques (Xpert MTB/RIF, culture, and smear test). Expert Choice 11.5®
software was used to perform matrix pairwise comparisons in light of the scale of Saaty [16].
Table 4 summarizes the required parameters for the pairwise comparison matrix. This
weighed analysis compared cost, effectiveness, time, and test analysis for each diagnostic
platform. This program assigns a weight to each of the alternatives relative to the criteria. The
total weight is distributed among the diagnostic alternatives, which were the electro-
immunosensor, Xpert MTB/RIF, culture and smear test. Table 5 shows the results obtained [29].
Figure 5. (a) Detection limit for the dot blot assay compared to the electro-immunosensor. (b, c, d) Analysis of impedance
variation for 0.5 μg/mL of analyte. (b) Impedance magnitude at 40–120 Hz, (c) impedance magnitude at 120–200 Hz, and
(d) impedance magnitude at 200–280 Hz.
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The AHP analysis confirmed that the designed electro-immunosensor is a superior alternative
for detection compared with traditional TB diagnostic techniques. For instance, it requires a
shorter time of analysis per test and allows high throughput screening (a single device handles
40 independent replicas), and even the identification of different M. tuberculosis epitopes by
varying the bio-recognition probe in each well. Despite these advantages, the electro-
immunosensor is not the preferred choice locally mainly due to its prohibitive price (attributed
to the cost of required bioreagents) and the untested effectiveness in clinical contexts.
Frequencies |Z| Ab |Z| HAS |Z| ESAT6
Average
(μ) Ab
Standard
Deviation (σ) Ab
Average (μ)
HSA
Standard
Deviation (σ) HSA
Average (μ)
ESAT6
Standard Deviation
(σ) ESAT6
40 0.1986 0.0070 0.2016 0.0114 0.5462 0.0264
50 0.1997 0.0067 0.1986 0.0116 0.5440 0.0254
60 0.2004 0.0065 0.1986 0.0118 0.5439 0.0260
70 0.1996 0.0065 0.2000 0.0112 0.5446 0.0260
80 0.2009 0.0068 0.1991 0.0114 0.5443 0.0259
90 0.2018 0.0071 0.1988 0.0109 0.5440 0.0256
100 0.2016 0.0068 0.1988 0.0114 0.5438 0.0260
110 0.2003 0.0070 0.1986 0.0113 0.5437 0.0260
120 0.2009 0.0070 0.1986 0.0114 0.5434 0.0263
130 0.1819 0.0083 0.2340 0.0320 0.5266 0.0292
140 0.1821 0.0084 0.2338 0.0317 0.5267 0.0288
150 0.1814 0.0083 0.2337 0.0318 0.5264 0.0292
160 0.1815 0.0084 0.2338 0.0316 0.5264 0.0294
170 0.1807 0.0081 0.2336 0.0315 0.5262 0.0295
180 0.1812 0.0085 0.2337 0.0319 0.5262 0.0296
190 0.1809 0.0082 0.2340 0.0315 0.5260 0.0294
200 0.1805 0.0084 0.2336 0.0318 0.5266 0.0291
210 0.1846 0.0022 0.2540 0.0373 0.4820 0.0153
220 0.1844 0.0020 0.2537 0.0372 0.4805 0.0156
230 0.1850 0.0021 0.2532 0.0371 0.4798 0.0154
240 0.1839 0.0019 0.2527 0.0372 0.4786 0.0159
250 0.1846 0.0021 0.2522 0.0370 0.4779 0.0163
260 0.1838 0.0023 0.2519 0.0368 0.4784 0.0169
270 0.1845 0.0019 0.2515 0.0371 0.4789 0.0177
280 0.1843 0.0022 0.2513 0.0367 0.4826 0.0144
Table 3. Impedance magnitude values (mean and standard deviation) of different analytes at 40–280 Hz.
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4. Case of study: Chagas
Development of methods that can facilitate low-cost diagnosis of infectious and particularly
neglected tropical diseases has been widely studied in the last few decades. In this section, we
outline the design, fabrication and evaluation of a portable system for the detection of Chagas
Disease during the Acute phase of the disease, called Chagas Biosense, as an alternative to
perform a quick, on-site, and low-cost diagnosis. Furthermore, we describe its potential impact
on alleviating the economic burden on the healthcare system by improving rural diagnostics of
Chagas in developing and tropical countries.
4.1. Theoretical framework
4.1.1. Fundamentals of Chagas disease
The World Health Organization (WHO) classifies 17 major parasitic and bacterial infections as
neglected tropical diseases (NTDs) [31]. NTDs are characterized by affecting vulnerable
Test Cost Time of
analysis
Probability of contamination Difficulty of analysis
with blood in sample
Test effectiveness
TBC
biosensor
7 USD
(without
labor and
overhead)
1 h Low: although it is a manual
process, there are mechanical
barriers to avoid filtration
between wells
It is based on antigen-
body recognition, so
bleeding is not supposed
to affect the results
Results confirm that
reliable data is obtained
with the biosensor
Xpert MTB/
RIF
98.10 USD 2 h None: completely automated There is no interference
after the pretreatment
High sensitivity,
specificity and
reproducibility. Avoid
false positive/negative
results
Culture
(MGIT)
36.56 USD 1 month Medium: microbial growth
can be affected by
accompanying microbiota
Bleeding does not affect
the results
Reliability between 70
and 90%
Smear
microscopy
test
4.07 USD More
than 1
day
None: it is a fast and direct
method
There is no interference
after the pretreatment
It depends on the
sample and technician.
Reliability can vary
between 22 and 80%
Table 4. Criteria for the establishment of the pairwise comparison matrix for the diagnostic techniques forM. tuberculosis.
Electro-immunosensor (%) Xpert MTB/RIF (%) Culture (%) Smear test (%)
Retail price 31.0 4.3 11.3 53.4
Analysis of tests 35.6 15.8 28.1 20.5
Effectiveness 10.6 14.4 54.3 20.8
Time of test 50.2 29.0 4.1 16.7
Global weights 32.5 16.7 22.5 28.3
Table 5. Local weights for each diagnostic platform.
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populations (where healthcare systems are generally inefficient), and their survival under
tropical and subtropical conditions [32]. American trypanosomiasis, better known as Chagas
disease, is one of the most common NTDs in the world, which is caused by the parasite
Trypanosoma cruzi. Recent estimates indicated that between 6 and 7 million people are infected
worldwide [32].
Chagas is a vector-born disease transmitted by triatomine insects. This hematophagous insect
of the Reduviidae family, transmits the disease while feeding [33]. The infection starts with the
movement of the parasite from the insect feces into human blood streams. From this point, the
disease will develop in two consecutive phases. First, the Acute phase, characterized for a high
number of parasites present in the bloodstream, lasting for about 4 to 8 weeks and showing
very mild or non-existent symptoms [34]. Second, the Chronic phase, where the immune
system of individuals is compromised and some organs are infested with the Trypanosoma
cruzi [34]. In fact, when the patient reaches the Chronic phase, the parasite invades the
digestive system and the heart tissues, which can cause damages that will be evidenced up to
20 years after the infection [35]. Most commonly, patients will manifest progressive heart
damage, which may eventually require a heart transplant [34, 35].
Nowadays, treatments to the disease include benznidazole and Nifurtimox. Both treatments
are 100% effective in killing the parasite and treating the disease if they are used at the
beginning of the Acute phase. The efficacy of both treatments decreases as the infection pro-
gresses [32].
4.1.2. Current diagnosis methods
Diagnosis of Chagas Disease is carried out by observation of the parasite in a blood sample by
means of microscopy methods, such as blood cultures, xenodiagnoses and thick drop, among
others. However, these methods only work during the Acute phase of the disease, due to the
important number of parasites in the bloodstream [9]. Diagnosis in the Chronic phase is
determined based on the medical history of the patient, and only if the patient has lived in an
endemic area. Thus, diagnosis during this phase relies on laboratory tests based on antibodies
specific for the disease, ELISA tests, and quick tests such as Chagas STAT-PAK® [36]. Table 6
summarizes the main characteristics of most popular diagnosis tests, as well as our system.
4.1.3. Chagas biosense concept
An effective detection method of Chagas Disease relies on the basic understanding of the
parasite behavior inside the human circulatory system. The parasite in its infectious stage
(metacyclic trypomastigote) reaches the circulatory system after the vector (triatomine insect)
defecates in a superficial skin wound. Once in the bloodstream, the parasite enters red blood
cells (RBCs), white blood cells (WBCs) or platelets, where the next development stage
(amastigote) begins and the parasite reproduces [37].
After infection, the parasite at the trypomastigote stage can be easily differentiated from blood
cells. For instance, RBCs have a diameter between 6.2 and 8.2 μm and a thickness between 0.8
and 1 μm [38], while the parasite has a length between 15 and 24 μm [39] and a width of
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approximately 1.09 μm [40]. These differences in size and density suggest the possibility of
using a microfluidic device as a separation platform.
Microfluidic devices have already been used in the detection of diseases such as malaria, HIV,
and tuberculosis. For example, the detection of HIV is attained by counting the number of CD4
+ T-lymphocytes cells in a blood sample, based on the fact that HIV leads to an increase in cell
concentration (to levels above 200 cells/mL) [41]. In the case of malaria, the parasite enters
RBCs and changes their weight and density, allowing their separation from healthy cells by
means of centripetal force [41].
4.2. In silico design
4.2.1. Microfluidics fundamentals
Fluid mechanics under the confinement of a microsystem differs from that at the macroscale. For
instance, parameters like viscosity, diffusion, adhesion forces and density become significant,
while gravity loses strength at the microscale [42]. One of the most important parameters in
microfluidics is the Reynolds number (Re), which can be estimated by the following equation:
Name Test category Use in
laboratory
Detection State Sample
volume
(μL)
Test
duration
(h.min)
Cost/
test
(USD)
Chagas Biosense
(BIOTROP)
Rapid assays No Direct detection of the
parasity Trypanosoma
cruzi by microfluidics
Acute 5 0.05 10.83
Chagas STAT-PAK®
(Chembio Diagnostic
Systems, Inc.)
No Detection of antibodies for
Trypanosoma cruzi by
immunochromatographic
assay
Chronic 10 0.20 —
HBK 740
IMUNOBLOT
LINHAS anti-T. cruzi
(Innogenetics,
Belgium)
Confirmatory
assays
Yes Indirect
immunofluorescence
antibody detection
10 1.50 0.19
IMUNOCRUZI®
(biolab-Merieux S.A.)
No Detection of antibodies by
immunoblot assay
10 18.00 20
TESA-blot (biolab-
Merieux S.A.)
Yes Detection of antibodies by
Western blot
10 4.00 —
CHAGAS HAI
IMUNOSERUM
(Laboratorio Lemos –
Polychaco)
Agglutination No Detection of specific
antibodies in the sample
by hemagglutination
10 1.50 0.33
CHAGAS-ELISA
(EBRAM Productos
Laboratoriais Ltda)
Enzyme
immunoassays
No Detection of antibodies in
the sample by ELISA test
10 1.40 1.02
Table 6. Compared analysis between Chagas biosense and some methods evaluated by the WHO.
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Re ¼
rvDh
μ
(1)
Where r is the density of the fluid, μ is the viscosity of the fluid, v the velocity of the fluid, and
Dh is the hydraulic diameter [43]. The Re can be understood as the ratio of inertial forces to
viscous forces [43]. In microfluidics, typical values of Re oscillate around 1, which correspond to
the laminar flow regimewhere viscous forces dominate [42, 44]. In addition, microfluidic devices
operating at low Re number can be used for particle separation in a predictable manner [44].
When particles are immersed in a fluid flowing in a microchannel, they are subjected to the Lift
force (FL), which drives them towards zones of higher shear stress [44]. The Lift force can be
calculated with the following equation:
FL ¼ rG
2CLa
4
p (2)
where G is the shear rate of the fluid and is given by G ¼ v=Dh, CL is the lift coefficient, which is
a function of the particle position in the channel, and ap is the diameter of the particle [44].
Particles are also subjected to a secondary force known as the Drag force (FD). This force is
generated by the curvature of the geometry leading to particle trajectories perpendicular to the
main flow direction [44]. The Drag force can be evaluated from the following equation:
FD ¼ 5:4∗10
4
πμDe1:63ap; De ¼ Re
ffiffiffiffiffiffi
Dh
2R
r
(3)
where De is the Dean number, which describes the effect of curvature in flow nature, and R is
the radius of curvature.
As these two forces counterbalance along the microchannel, particle separation is promoted as a
strong function of the particle diameter [45]. Thus, the relationship between ap, FL and FD is given
by the following set of inequalities, which state that for particles with a large diameter, the domi-
nant forcewill be FL. By contrast, if the particle has a small diameter, the dominant forcewill be FD.
ap1 > ap2 > ap3;
FL1
FD1
>
FL2
FD2
>
FL3
FD3
(4)
4.2.2. Simulations
Prior to microchannel fabrication, particle separation was evaluated in silico with the aid of
COMSOLMultiphysics®. This tool allowed us to test different microchannel curvatures, diameters
and lengths. To set up the simulations, the Computational Fluid Dynamics (CFD) and particle
tracing modules were coupled to study the separation of parasites from RBCs for different
microchannel configurations. A non-slip condition was defined at the boundaries. Figure 6 shows
the tested design, which consisted of 5 turns of a 0.5 mm wide microchannel that ended up in 4
outlets.
Proper meshing was determined from a mesh convergence analysis by evaluating the magnitude
of flow velocity at different locations within the domain. Convergence was met when there was
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less than 2% change on themagnitude of the velocity at each location after duplicating the number
of mesh elements in the domain [46]. The parameters for the simulations are listed in Table 7:
4.3. Prototypes fabrication
Different manufacturing strategies were used to fabricate the device prototype. These strate-
gies were classified into chemical etching and physical treatments strategies and are described
in the following sections.
4.3.1. Chemical etching: photolithography
Chemical etching is a process in which microstructures are generated by the chemical abrasion
of a material. Through this process, microstructures can be fabricated on a glass substrate by
using hydrofluoric acid (HF) as the etching agent [47]. The protocol for manufacturing the
prototype is shown in Figure 7a. Briefly, a photoresist layer was spin coated onto a glass slide
prior to photolithography (Figure 7a). The glass slide was then exposed to HF for 15 seconds to
obtain the microchannel. PDMS was adhered to the glass via oxygen plasma irradiation, and
served as a sealing layer (Figure 7a).
4.3.2. Physical treatment: laser engraving and cutting
Laser engraving and cutting were used as physical techniques for the fabrication of the
prototype onto a PMMA substrate. The overall manufacturing process is shown in Figure 7b.
Figure 6. Computational domain and meshing.
Fluid density 1030 (Kg/m3)
Fluid dynamic viscosity 1.5  103 (Pa s)
Input velocity 0.1 (m/s)
Parasite density 1030 (Kg/m3)
Parasite diameter 30 (μm)
RBCs density 1030 (Kg/m3)
RBCs diameter 6 (μm)
Table 7. Simulation parameters.
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In brief, the design was engraved into PMMAwith a laser cutter (TROTEC® Speedy 100, 60 w).
Sealing of the microchannel was attained by application of methyl methacrylate and constant
pressure between the layers.
4.4. Results
Currently, the described device is at a design stage. Accordingly, parasite separation has been
mainly tested in silico with the aid of the Multiphysics simulation platform COMSOL®.
Nonetheless, simulations have given us important insights to be taken into account for prepar-
ing more robust prototypes
4.4.1. Simulations
Convergence was attained with 150,000 triangular mesh elements (Figure 8). Velocity profiles
and particle distributions at the outlets are shown in Figures 9 and 10, respectively.
Maximal separation of parasites fromRBCswas evidenced in outlets 1 and 3. Nonetheless, there is
still a percentage of cross-contamination at the outlets (approximately 25% per outlet). This could
be overcome by changing the length of the microchannel or increasing the number of outlets.
4.4.2. Prototypes and proof-of-concept
Functionality and proper sealing of prototypes was tested with water as flowing fluid. Syrin-
ges were connected at the inlets through MEDEX® fr 6 urethral nelaton catheters. A Touch
Screen (Cole-Parmer®, USA) syringe pump was used to control water flow. Laser engraved
prototypes showed leaks when subjected to pressure. In addition, their microchannels dimen-
sions doubled those expected since the manufacturing technique had a low precision in
micrometric scales. Furthermore, in the chemical etched prototype, fluid flow was restricted
Figure 7. Manufacturing process of biomicrosystems. (a) Chemical etching process, and (b) laser engraving and cutting.
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Figure 8. Mesh convergence analysis.
Figure 9. Particle distribution and velocity profile obtained in COMSOL Multiphysics®.
Figure 10. Particle distribution per outlet when simulating 600 particles (100 parasite particles and 500 RBCs particles).
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due to the high hydraulic resistance inside the microsystem. To overcome these issues, several
strategies can be implemented including a push-in fitting at the inlets to minimize leakages;
improved adhesion processes at the interfaces and etched channels with larger dimensions.
4.5. Cost analysis
4.5.1. Disease cost and impact of the device
According to Lee et al. [48], the worldwide expenditure on Chagas Disease is estimated to lay
between $1860282,994 and $16380807,623 USD. 78.35% of which correspond to Latin-America
while 18.6% are from the United States and Canada. These costs are principally derived from
the treatment of cardiac and digestive complications associated with the disease during the
Chronic phase. This roughly represents expenditures of $5900 USD per patient. By contrast,
the costs during the Acute phase represent only a single expenditure of $200 USD per patient,
which makes diagnosis for the Acute phase the best strategy to reduce the economic burden of
treatments on the health care system [49].
The proposed microfluidic system serves as a portable diagnostic device that eliminates the
need to attend to specialized laboratories to obtain a diagnosis. This allows rural populations
at endemic areas to have a prompt knowledge of their state of health regarding the presence of
the Chagas parasite. Also, being able to obtain a diagnosis during the Acute phase will help
government agencies to assess the real number of Chagas disease cases, which will result in
better awareness and additional research funding.
The expenditure per test of diagnosis varies depending on the stage of the disease. As depicted
in Table 5, most of the procedures for Chronic phase diagnosis have an approximate cost of $1
USD per test. However, some of the commercially available tests such as the HBK 740
IMUNOBLOT LINHAS anti-T cruzi could have a cost as high as $20 USD per individual test
[37]. By contrast, blood testing for Acute phase diagnosis has an approximate cost of $17 USD
per patient (Tauramena local Hospital, Colombia).
The Acute phase diagnostic device proposed in this section has an approximate cost of $8 and
$4 USD if manufactured via chemical or physical processes, respectively. These costs corre-
spond to expenditures on materials and equipment. In addition to low manufacturing costs,
this device does not require specialized laboratory equipment for the diagnosis, allowing its
use at remote rural areas, which are usually endemic areas as well.
4.5.2. Future perspectives
Although geometries were verified by simulation processes, there is still a gap between simu-
lated geometries and manufactured prototypes. Sealing techniques must be improved to avoid
leaks and increase the life of the device. Also, the microfluidic separation device needs to be
coupled with sensing techniques to unequivocally identify the parasite. This could be achieved
by including specific antibodies towards Trypanosoma cruzi or by placing electrodes at the
outlets to determine effective separation by electrical measurements such as electrochemical
impedance spectroscopy (EIS).
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5. Concluding remarks and future perspectives
Point-of-care devices are ideal for providing reliable information in a fast, user-friendly, accu-
rate, and low-cost manner. Electro-immunosensors offer an attractive option for pathogen
detection with high sensitivity and affinity, which can ultimately respond to the challenge of
bringing electrochemical sensing techniques to patients. Also, microfluidic separators provide
an avenue for isolating and rapidly estimating the relative abundance of pathogens in biolog-
ical fluids. Rapid diagnosis devices such as those introduced here facilitate clinical decision
making and effective treatment thereby leading to greater patient survival rates. The presented
case studies show examples in which LoC technology is exploited for pathogen detection.
Although the devices show promising results towards early diagnosis of HPV, Tuberculosis
and Chagas disease, further work is still needed to bring the developments to commercial
success. For instance, the possibility of effectively handling information by end users should be
included in the proposed technologies as well as their integration with internet of things (IoT)
and cloud computing technology. Also, manufacturing methods that involve drilling can be
easily substituted with injection technology, which may reduce costs and time of production.
Point-of-care devices constitute the ideal direction towards providing a reliable diagnosis in
remote areas without the need of a specialized laboratories or clinical facilities.
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